Traumatic brain injury: Oxidative stress and novel anti-oxidants such as mitoquinone and edaravone
![Thumbnail](/xmlui/bitstream/handle/10576/47942/antioxidants-09-00943-v2.pdf.jpg?sequence=3&isAllowed=y)
View/ Open
Date
2020Author
Ismail, HeleneShakkour, Zaynab
Tabet, Maha
Abdelhady, Samar
Kobaisi, Abir
Abedi, Reem
Nasrallah, Leila
Pintus, Gianfranco
Al-Dhaheri, Yusra
Mondello, Stefania
El-Khoury, Riyad
Eid, Ali H.
Kobeissy, Firas
Salameh, Johnny
...show more authors ...show less authors
Metadata
Show full item recordAbstract
Traumatic brain injury (TBI) is a major health concern worldwide and is classified based on severity into mild, moderate, and severe. The mechanical injury in TBI leads to a metabolic and ionic imbalance, which eventually leads to excessive production of reactive oxygen species (ROS) and a state of oxidative stress. To date, no drug has been approved by the food and drug administration (FDA) for the treatment of TBI. Nevertheless, it is thought that targeting the pathology mechanisms would alleviate the consequences of TBI. For that purpose, antioxidants have been considered as treatment options in TBI and were shown to have a neuroprotective effect. In this review, we will discuss oxidative stress in TBI, the history of antioxidant utilization in the treatment of TBI, and we will focus on two novel antioxidants, mitoquinone (MitoQ) and edaravone. MitoQ can cross the blood brain barrier and cellular membranes to accumulate in the mitochondria and is thought to activate the Nrf2/ARE pathway leading to an increase in the expression of antioxidant enzymes. Edaravone is a free radical scavenger that leads to the mitigation of damage resulting from oxidative stress with a possible association to the activation of the Nrf2/ARE pathway as well.
Collections
- Biomedical Sciences [711 items ]